Literature DB >> 8246446

Location and alternative splicing of type XIII collagen RNA in the early human placenta.

M Juvonen1, T Pihlajaniemi, H Autio-Harmainen.   

Abstract

BACKGROUND: Type XIII collagen is widely distributed in the fetus. It is characterized by complex alternative splicing of its primary transcripts in regions corresponding to nine exons of the gene. EXPERIMENTAL
DESIGN: Localization of type XIII collagen mRNAs in early placentas was determined by in situ hybridization. Reverse-transcription-polymerase chain reactions were used to examine alternative splicing of nine exons in villous and decidual mRNAs.
RESULTS: An intense in situ hybridization signal was observed in the fibroblastoid stromal cells of the placental villi. A moderate signal was found in the endothelial cells of developing capillaries and the cells of the cytotrophoblastic columns. Furthermore, mRNAs were detected in the large decidual cells of the decidual membrane and the stromal cells of the gestational endometrium, but not in the epithelial cells in the endometrial glands. Five combinations of exons 3B, 4A, 4B and 5, encoding half of the COL1 domain, were found. The combination lacking exons 3B-5 was the major variant in both villous and decidual mRNAs. Three combinations of exons 12 and 13 encoding the NC2 domain were found, the long variant containing either 12 or 13 sequences being the major variant in the villi while nearly equal amounts of long and short variants lacking both 12 and 13 sequences were observed in the decidua. Four variants of exons 29, 33 and 37, encoding parts of COL3 and NC4, were found as splicing out of exon 37 was not detected. The major variants in both mRNAs were two that lacked exon 29 and either lacked or contained exon 33 sequences.
CONCLUSIONS: Type XIII collagen mRNAs were located in the placenta. Due to alternative splicing, the lengths of the COL1 and NC2 domains of this collagen vary from 57 to 104 and from 12 to 34 amino acids, respectively. The COL3 domain varies between 208 and 235 residues, whereas the NC4 is 18 residues.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8246446

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  6 in total

1.  A short sequence in the N-terminal region is required for the trimerization of type XIII collagen and is conserved in other collagenous transmembrane proteins.

Authors:  A Snellman; H Tu; T Väisänen; A P Kvist; P Huhtala; T Pihlajaniemi
Journal:  EMBO J       Date:  2000-10-02       Impact factor: 11.598

2.  Distribution of type XV collagen transcripts in human tissue and their production by muscle cells and fibroblasts.

Authors:  S Kivirikko; J Saarela; J C Myers; H Autio-Harmainen; T Pihlajaniemi
Journal:  Am J Pathol       Date:  1995-11       Impact factor: 4.307

3.  Abnormal adherence junctions in the heart and reduced angiogenesis in transgenic mice overexpressing mutant type XIII collagen.

Authors:  M Sund; R Ylönen; A Tuomisto; R Sormunen; J Tahkola; A P Kvist; S Kontusaari; H Autio-Harmainen; T Pihlajaniemi
Journal:  EMBO J       Date:  2001-09-17       Impact factor: 11.598

4.  Lack of cytosolic and transmembrane domains of type XIII collagen results in progressive myopathy.

Authors:  A P Kvist; A Latvanlehto; M Sund; L Eklund; T Väisänen; P Hägg; R Sormunen; J Komulainen; R Fässler; T Pihlajaniemi
Journal:  Am J Pathol       Date:  2001-10       Impact factor: 4.307

5.  Alternative splicing in normal and pathological human placentas is correlated to genetic variants.

Authors:  Camino S M Ruano; Clara Apicella; Céline Méhats; Daniel Vaiman; Sébastien Jacques; Géraldine Gascoin; Cassandra Gaspar; Francisco Miralles
Journal:  Hum Genet       Date:  2021-01-12       Impact factor: 4.132

6.  Membrane-associated collagens with interrupted triple-helices (MACITs): evolution from a bilaterian common ancestor and functional conservation in C. elegans.

Authors:  Hongmin Tu; Pirkko Huhtala; Hang-Mao Lee; Josephine C Adams; Taina Pihlajaniemi
Journal:  BMC Evol Biol       Date:  2015-12-14       Impact factor: 3.260

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.